Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 10/20 | 0.50 |
| ▸ | RAB9A | P51151 | 10/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.42 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964433 | 0.83 | NPC1 (0.59) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL12974 | 0.81 | HPGD (0.73) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL9341650 | 0.80 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL1186494 | 0.79 | GUSB (0.51) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL14561782 | 0.79 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL10039243 | 0.79 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL7412244 | 0.79 | RAB9A (0.71) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL13393581 | 0.79 | TRPM8 (0.60) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL8118542 | 0.79 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2HPGDTSHR | |
| SCHEMBL3910760 | 0.79 | MECP2 (0.69) | NPC1RAB9ASMN1; SMN2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-03-03 | — | — | US | disclosed |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-05-02 | — | — | US | disclosed |
| EP-3442960-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017178510-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-19 | — | — | WO | disclosed |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | ALMIRALL, S.A. (ES) | 2014-01-02 | — | — | US | disclosed |
| US-8569285-B2 | Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8536165-B2 | Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors | ALMIRALL, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-2431360-B1 | Derivatives of dihydrobenzoxathiazepine, method of preparing same and pharmaceutical compositions containing them as well as their uses as modulators of AMPA receptors | SERVIER LAB (FR) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012088316-A1 | 2-ALKYL-5-PHENYL OXADIAZOLE-CARBAZOLE HOSTS FOR GUEST EMITTERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088316-A1 | 2-ALKYL-5-PHENYL OXADIAZOLE-CARBAZOLE HOSTS FOR GUEST EMITTERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
| EP-0800393-A4 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-05-06 | — | — | EP | disclosed |
| EP-0794774-A4 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 1998-04-29 | — | — | EP | disclosed |
| EP-0828493-A1 | 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0827495-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0800393-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-10-15 | — | — | EP | disclosed |
| EP-0794774-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1997003945-A1 | SUBSTITUTED-PENT-4-YNOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996038150-A1 | 4.4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS-MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996019995-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-ONE MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996019988-A1 | 4,4-(DISUBSTITUTED)CYCLOHEXAN-1-OLS MONOMERS AND RELATED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10577360-B2 | Arylamide derivatives having multimodal activity against pain | OPRD1, TRPV1, OPRL1 | APP 1629/4885NPC1 2162/4885RAB9A 1982/4885 |
| US-20190127357-A1 | ARYLAMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, TRPV1, OPRL1 | APP 1629/4885NPC1 2162/4885RAB9A 1982/4885 |
| US-20140005178-A1 | AZABIPHENYLAMINOBENZOIC ACID DERIVATIVES AS DHODH INHIBITORS | DHODH, DPYD, DLD | APP 4593/4885NPC1 1549/4885RAB9A 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.